Health
Novel breast cancer therapy candidate enters clinical study – Mirage News
Kiran Dhillon In a UW Medicine cancer immunotherapy lab, research scientist Nick Drovetto puts a rack of samples into a liquid nitrogen tank. A Phase 1…
A Phase 1 patient trial of the novel, oral therapy candidate, Alpha TEA, for advanced HER2 positive breast cancer is now underway. Veana Therpeutics, Inc., and UW Medicine will collaborate on the clinical testing of Veana’s lead agent – an alpha TEA lysine salt, in combination with the monoclonal antibody, trastuzumab, brand name Herceptin.
In HER2 positive breast cancer, the tumor cells produce a higher-than-usual level of the HER2protein that drives cancer growth and spread.
Alpha TEA lysine…
-
General14 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News20 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business22 hours agoBell Potter names the best ASX shares to buy in October
-
General19 hours agoAustralia welcomes Gaza peace progress, hostage release